Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: PTCT stock price vs HIMS: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at HIMS's multiple
Needs HIMS P/E.
Implied fair value · at PTCT's multiple
Needs PTCT P/E.
Snapshot Sep 4, 4:00 PM ET
Metric by metric
Where each company leads, and how wide the gap is.
Growth edge
Pricing power
Operating leverage
Multiple premium
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: PTCT FY 2025 (ended Dec 31, 2025) · HIMS FY 2025 (ended Dec 31, 2025).
Trendline
Five fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Capital structure 95% equity / 5% debt · EV / Revenue 2.38x · EV / EBITDA 5.50x
Capital structure 0% equity / 100% debt · EV / Revenue 0.47x · EV / EBITDA 7.55x
PTCT carries the larger enterprise value at $4.13B against $1.11B; HIMS trades on the lower EV / Revenue multiple (0.47x vs 2.38x); PTCT on the lower EV / EBITDA (5.50x vs 7.55x).
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
PTC Therapeutics, Inc. · implied price per share
At least 3 of the last 5 annual free-cash-flow observations must be positive.
HIMS & HERS HEALTH, INC. · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Debt / equity
Total debt against shareholders' equity
-1.40x
2.48x
Net debt / EBITDA
Leverage against operating earnings
-2.21x
7.55x
Cash and equivalents
Liquid reserves on the balance sheet
$1.95B
$228.62M
Total debt
Interest-bearing obligations outstanding
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
VERTEX PHARMACEUTICALS INC / MA
PTCT vs VRTX
Sarepta Therapeutics, Inc.
PTCT vs SRPT
BIOMARIN PHARMACEUTICAL INC
PTCT vs BMRN
ALNYLAM PHARMACEUTICALS, INC.
PTCT vs ALNY
Teladoc Health, Inc.
PTCT vs TDOC
GoodRx Holdings, Inc.
PTCT vs GDRX
CLOVER HEALTH INVESTMENTS, CORP. /DE
PTCT vs CLOV
Roivant Sciences Ltd.
PTCT vs ROIV
$286.63M
$1.34B
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.
